{"version": "https://jsonfeed.org/version/1.1", "title": "Sharemaestro Newsreel: Austria Drug Manufacturers - General news", "home_page_url": "https://sharemaestro.com/newsreel/at/healthcare/drug-manufacturers-general/", "feed_url": "https://sharemaestro.com/newsreel/at/healthcare/drug-manufacturers-general/feed.json", "description": "Latest Drug Manufacturers - General company headlines from Austria, newest first, with source links and direct routes to company research and sentiment.", "language": "en", "items": [{"id": "source:209c7ec5a3bdfb62d9476f6af4aa8804531855d96c1744e17ad789a7b9de2d79", "url": "https://finance.yahoo.com/healthcare/articles/3-large-cap-stocks-watch-135000158.html", "external_url": "https://finance.yahoo.com/healthcare/articles/3-large-cap-stocks-watch-135000158.html", "title": "3 Large-Cap Stocks to Watch as Pharma Recovery Takes Hold", "content_text": "The drug and biotechnology sector has had a strong recovery so far in 2026, driven by innovation, robust quarterly performances, optimistic full-year outlooks, positive regulatory updates and a major wave of M&A activity. However, it faces its share of headwinds like slower-than-expected launches of newer therapies, looming patent expirations for several blockbuster drugs and ongoing policy and pricing uncertainty in major markets. Competitive pressure, particularly in fast-growing areas like obesity/cardiometabolicand cancer treatments, also remains intense. Despite these headwinds, the indus", "date_published": "2026-08-14T13:50:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "LLYC"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "LLYC", "name": "Eli Lilly and Company", "sentiment_url": "https://sharemaestro.com/sentiment/445698db-0930-4e3d-97d8-e06e548856f7/"}]}}, {"id": "source:716db2c758fe7563d890b3fd84cd08700f39c2dc0800cb2ca92c80723134e873", "url": "https://seekingalpha.com/news/4633188-lantheus-tau-pet-imaging-agent-approved-alzheimers?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "external_url": "https://seekingalpha.com/news/4633188-lantheus-tau-pet-imaging-agent-approved-alzheimers?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "title": "Lantheus gains FDA nod for tau PET imaging agent in Alzheimer\u2019s", "content_text": "[US Food and Drug Administration (FDA)] Lantheus Holdings (LNTH [https://seekingalpha.com/symbol/LNTH]) on Friday announced the FDA approval of Tauklarify, a radiodiagnostic agent designed to identify tau pathology of the brain in adults with Alzheimer\u2019s disease through positron emission tomography (PET). Specifically, the approval allows the use of Tauklarify in cognitively impaired adults who are investigated for Alzheimer\u2019s disease to detect if there is any tau neurofibrillary tangle pathology causing the condition. Patients should undergo diagnostic tests, such as PET scans, to determine t", "date_published": "2026-08-14T12:31:50+00:00", "authors": [{"name": "seekingalpha.com"}], "tags": ["Regulatory and legal", "LLYC"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "LLYC", "name": "Eli Lilly and Company", "sentiment_url": "https://sharemaestro.com/sentiment/445698db-0930-4e3d-97d8-e06e548856f7/"}]}}, {"id": "source:feb4c10773207b089470a45f64ed6c862c294f24a43dcb044c603c039d23c4d0", "url": "https://finance.yahoo.com/m/c7509af1-9542-320b-b10c-f73523ccdd58/eli-lilly-stock-nears-buy.html", "external_url": "https://finance.yahoo.com/m/c7509af1-9542-320b-b10c-f73523ccdd58/eli-lilly-stock-nears-buy.html", "title": "Eli Lilly Stock Nears Buy Point After Earnings-Fueled Gains", "content_text": "While Eli Lilly isn't a perfect technical setup, it's still a fundamental powerhouse that could be worth considering. Continue Reading", "date_published": "2026-08-14T12:00:27+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "LLYC"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "LLYC", "name": "Eli Lilly and Company", "sentiment_url": "https://sharemaestro.com/sentiment/445698db-0930-4e3d-97d8-e06e548856f7/"}]}}, {"id": "source:e6793ea00b43a8209175c2cdffd939d23887d050c43a1a645355d97124e49d99", "url": "https://www.nasdaq.com/articles/fidelity-healthcare-etf-vs-ishares-pharma-fund-which-wins", "external_url": "https://www.nasdaq.com/articles/fidelity-healthcare-etf-vs-ishares-pharma-fund-which-wins", "title": "Fidelity Healthcare ETF vs. iShares Pharma Fund: Which Wins?", "content_text": "Key Points Fidelity MSCI Health Care Index ETF offers a lower expense ratio of 0.08% compared to the 0.37% fee for iShares U.S. Pharmaceuticals ETF. iShares' fund provides concentrated exposure to 56 pharmaceutical stocks, while Fidelity's holds 338 stocks across the broader healthcare sector. The iShares fund delivered a higher one-year total return of 60% as of Aug. 10, 2026.10 stocks we like better than Fidelity Covington Trust - Fidelity Msci Health Care Index ETF \u203a While Fidelity MSCI Health Care Index ETF(NYSEMKT:FHLC) provides broad healthcare exposure at a very low cost, iShares U.S. P", "date_published": "2026-08-14T11:35:01+00:00", "authors": [{"name": "nasdaq.com"}], "tags": ["Market update", "LLYC"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "LLYC", "name": "Eli Lilly and Company", "sentiment_url": "https://sharemaestro.com/sentiment/445698db-0930-4e3d-97d8-e06e548856f7/"}]}}, {"id": "source:cafe33c7ee73f6b984147b313061d92fcd1333eadfcaa3189464866c61cca1ba", "url": "https://finance.yahoo.com/markets/stocks/articles/5-revealing-analyst-questions-eli-054900384.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/5-revealing-analyst-questions-eli-054900384.html", "title": "5 Revealing Analyst Questions From Eli Lilly\u2019s Q2 Earnings Call", "content_text": "5 Revealing Analyst Questions From Eli Lilly's Q2 Earnings Call Eli Lilly's second quarter was marked by a positive market reaction, despite the company missing Wall Street's revenue expectations. Management credited growth in key products\u2014especially in cardiometabolic health, oncology, and neuroscience\u2014as drivers of performance. CEO David Ricks pointed to \"robust revenue growth across all Key Products and major geographies,\" noting the strength of new medicines and expansion in emerging markets. The launch of Foundayo in the U.S. and UAE, along with ongoing investments in manufacturing and R&", "date_published": "2026-08-14T05:49:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "LLYC"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "LLYC", "name": "Eli Lilly and Company", "sentiment_url": "https://sharemaestro.com/sentiment/445698db-0930-4e3d-97d8-e06e548856f7/"}]}}, {"id": "source:0900c281a1b7e54999dfd196bbfe90a2a2a5cb52fdbe999e1d2a91793c625390", "url": "https://finance.yahoo.com/healthcare/articles/pfizer-valneva-lyme-disease-vaccine-050000585.html", "external_url": "https://finance.yahoo.com/healthcare/articles/pfizer-valneva-lyme-disease-vaccine-050000585.html", "title": "Pfizer and Valneva\u2019s Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency", "content_text": "Submission based on favorable efficacy and safety results from Phase 3 VALOR trial NEW YORK & LYON, France, August 14, 2026--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for PF-07307405, the companies' 6-valent outer surface protein A (OspA)-based Lyme disease vaccine candidate and will begin its assessment of the application. The application is based on encouraging efficacy of more than 70% observed in the Phase 3 VALOR \"Vaccine Ag", "date_published": "2026-08-14T05:00:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "PFE"], "_sharemaestro": {"country": "Austria", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "PFE", "name": "Pfizer Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/6d38e875-5b6e-4520-a422-46060912e64a/"}]}}, {"id": "source:248772e86f849c54af48203e1ed82ca5c5a36ecd4687869763f578f9e29f78bd", "url": "https://finance.yahoo.com/healthcare/articles/could-abbvie-inc-abbv-win-233835472.html", "external_url": "https://finance.yahoo.com/healthcare/articles/could-abbvie-inc-abbv-win-233835472.html", "title": "Could AbbVie Inc. (ABBV) Win as Genmab A/S (GMAB) Faces a New Regulatory Test for Epcoritamab?", "content_text": "On July 23, Genmab A/S (NASDAQ:GMAB) and AbbVie Inc. (NYSE:ABBV) clarified a key clinical setback regarding their jointly developed T-cell engaging bispecific antibody, epcoritamab (DuoBody-CD3xCD20). The Phase 3 EPCORE DLBCL-1 study evaluated epcoritamab monotherapy against investigator's choice of chemoimmunotherapy in transplant-ineligible adults with relapsed/refractory diffuse large B-cell lymphoma. The clarification confirmed that in the United States, where overall survival was the sole primary endpoint, the trial failed to demonstrate a statistically significant improvement, missing it", "date_published": "2026-08-13T23:38:35+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Regulatory and legal", "ABBV"], "_sharemaestro": {"country": "Austria", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ABBV", "name": "AbbVie Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/08efad69-cb19-4d91-96ec-5ca4e3b9d43e/"}]}}, {"id": "source:c3a98a5f8747a521982b0d128ec0396d98d710f52be0af746179603a914f830a", "url": "https://finance.yahoo.com/healthcare/articles/johnson-johnson-jnj-5-5b-230726728.html", "external_url": "https://finance.yahoo.com/healthcare/articles/johnson-johnson-jnj-5-5b-230726728.html", "title": "Johnson & Johnson (JNJ)\u2019s $5.5B Talc Settlement: Turning Point or Temporary Relief?", "content_text": "The World Health Organization projects that the share of the world's population aged 60 years and older will almost double from 12% in 2015 to 22% by 2050. The Population Reference Bureau expects the number of Americans aged 65 and older to climb from 58 million in 2022 to 82 million by 2050. The aging population is fueling demand for healthcare. US healthcare spending is forecast to hit $6 trillion in 2026 from $5.7 trillion in 2025. This trend reflects an expanding market for medical products companies. Yet for large healthcare companies, legal issues can erode the benefits of favorable mark", "date_published": "2026-08-13T23:07:26+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "JNJ"], "_sharemaestro": {"country": "Austria", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "JNJ", "name": "Johnson & Johnson", "sentiment_url": "https://sharemaestro.com/sentiment/5cb5b173-9404-403f-96e5-f1e000f3ec40/"}]}}, {"id": "source:fc6f9ec80ab7f72145e43545e812f5b77553f112e9ad3ad2c9cb1395394825e5", "url": "https://finance.yahoo.com/healthcare/articles/could-merck-co-inc-mrk-214608790.html", "external_url": "https://finance.yahoo.com/healthcare/articles/could-merck-co-inc-mrk-214608790.html", "title": "Could Merck & Co., Inc. (MRK) and Gilead Sciences, Inc. (GILD)\u2019s Partnership Create the Next Big Pharma Growth Engine", "content_text": "Two biopharma giants, Merck & Co., Inc. (NYSE:MRK) and Gilead Sciences, Inc. (NASDAQ:GILD), are proving that in modern drug development, the biggest catalyst isn't always competing head-to-head; it is knowing when to join forces. While both companies reported their first-quarter 2026 earnings earlier this year, their recent double dose of clinical and regulatory breakthroughs across oncology and virology shows how strategic alliances can reshape two massive therapeutic markets at once.Could Merck & Co., Inc. (MRK) and Gilead Sciences, Inc. (GILD)\u2019s Partnership Create the Next Big Pharma Growth", "date_published": "2026-08-13T21:46:08+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "GILD"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "GILD", "name": "Gilead Sciences, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/4671d9b0-cfe6-4289-a9c5-3334d8b946be/"}]}}, {"id": "source:0cf9b0bafc74581624313018706925e5b7ffbaa1f8371efffb9791a217b0b884", "url": "https://finance.yahoo.com/healthcare/articles/could-abbvie-inc-abbv-post-213306053.html", "external_url": "https://finance.yahoo.com/healthcare/articles/could-abbvie-inc-abbv-post-213306053.html", "title": "Could AbbVie Inc. (ABBV)\u2019s Post-Humira Transformation Drive the Next Phase of Growth?", "content_text": "AbbVie Inc. (NYSE:ABBV) reported its first-quarter 2026 financial results, delivering worldwide net revenues of $15.002 billion, an increase of 12.4% on a reported basis (10.3% operationally). The company posted GAAP diluted EPS of $0.39 and adjusted diluted EPS of $2.65, which exceeded internal expectations despite including a $0.41 per share unfavorable impact from acquired IPR&D and milestone expenses. Grounded in this solid operational momentum, ABBV raised its full-year 2026 adjusted diluted EPS guidance range to $14.08\u2013$14.28. Adding to its commercial trajectory, AbbVie's Allergan Aesthe", "date_published": "2026-08-13T21:33:06+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "ABBV"], "_sharemaestro": {"country": "Austria", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ABBV", "name": "AbbVie Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/08efad69-cb19-4d91-96ec-5ca4e3b9d43e/"}]}}, {"id": "source:b86a19034e00afa9d2e6cf46ad3ac437d2c17839da92b496fd0c18240c6c4e29", "url": "https://finance.yahoo.com/healthcare/articles/u-fda-grants-accelerated-approval-211200307.html", "external_url": "https://finance.yahoo.com/healthcare/articles/u-fda-grants-accelerated-approval-211200307.html", "title": "U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS\u2122, in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for Patients with Multiple Myeloma, as Early as First Relapse", "content_text": "Product Image (Photo: Bristol Myers Squibb)ZENBEXUS\u2122 (iberdomide) Logo Approval based on EXCALIBER-RRMM results showing ZDd doubled minimal residual disease-negative complete response rates versus daratumumab, bortezomib and dexamethasone (41% vs. 21%) in relapsed or refractory multiple myeloma(1) ZENBEXUS marks the arrival of a new treatment class, representing the next chapter in Bristol Myers Squibb's targeted protein degradation platform PRINCETON, N.J., August 13, 2026--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has a", "date_published": "2026-08-13T21:12:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "BMYS"], "_sharemaestro": {"country": "Austria", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "BMYS", "name": "Bristol-Myers Squibb Company", "sentiment_url": "https://sharemaestro.com/sentiment/f6173bbe-95b7-4b6d-a943-9a5f9b3dfe02/"}]}}, {"id": "source:06c9383a28c831d166e244315bed34ee2122d4e28940a6a805108264a483d25b", "url": "https://finance.yahoo.com/markets/stocks/articles/merck-mrk-stock-fair-value-200750935.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/merck-mrk-stock-fair-value-200750935.html", "title": "Merck (MRK) Stock Fair Value Edges Higher After Analysts Back Pipeline Progress", "content_text": "Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Price target commentary for Merck has shifted toward a US$140 to US$155 range, anchored by a modest uplift in fair value from US$132.78 to US$136.85. Analysts link these higher targets to research that highlights Merck's pipeline progress, recent business development moves and continued focus on late stage therapeutics. As you read on, you will see how to track these moving pieces and what they could mean for the evolving Merck story in the coming years. Stay updated as the F", "date_published": "2026-08-13T20:07:50+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Analyst action", "MRK"], "_sharemaestro": {"country": "Austria", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "MRK", "name": "Merck & Co., Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/0211e6e8-c5d1-4887-83fc-5f88917de5ec/"}]}}, {"id": "source:364eedca97d998b6f754e2e7ebee016c2c8b9301ab4ad1d1bea0c30e18b20027", "url": "https://finance.yahoo.com/healthcare/articles/vivani-medical-reports-second-quarter-200500168.html", "external_url": "https://finance.yahoo.com/healthcare/articles/vivani-medical-reports-second-quarter-200500168.html", "title": "Vivani Medical Reports Second Quarter 2026 Financial Results and Provides Business Update", "content_text": "Vivani Medical, Inc. All participants successfully dosed in SLIM-1\u2122, the Company's first-in-human Phase 1 trial of NPM-139, a miniature, ultra long-acting semaglutide implant for chronic weight management; top-line data expected in November 2026 Company entered into non-exclusive agreement with Novo Nordisk to evaluate NPM-139 and Vivani's proprietary NanoPortal\u2122 technology Completion of the Cortigent-ClearOne merger into Cortigent Holdings and initiation of trading on the Nasdaq exchange under ticker symbol CRGT anticipated in the third quarter of 2026 ALAMEDA, Calif., Aug. 13, 2026 (GLOBE NE", "date_published": "2026-08-13T20:05:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Deals and strategy", "NNO2"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "NNO2", "name": "Novo Nordisk A/S", "sentiment_url": "https://sharemaestro.com/sentiment/fcb49788-2486-40a0-adc0-252e820a9044/"}]}}, {"id": "source:0307dd02aa0975f7f8405c50db19c72c2cdf264792b461807601c006f7de5fed", "url": "https://finance.yahoo.com/healthcare/articles/assembly-biosciences-reports-second-quarter-200000615.html", "external_url": "https://finance.yahoo.com/healthcare/articles/assembly-biosciences-reports-second-quarter-200000615.html", "title": "Assembly Biosciences Reports Second Quarter 2026 Financial Results and Recent Updates", "content_text": "Assembly Biosciences, Inc. \u2013 Expanded ABI-6250 clinical development into cholestatic liver diseases, including primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) \u2013 \u2013 Completed $115 million gross financing to support advancement of pipeline programs through key development milestones \u2013 \u2013 GS-1179 (formerly ABI-1179) selected to advance in HSV HPI program, with Phase 2 initiation expected by year-end 2026 \u2013 \u2013 Cash runway projected into 2029, including first $75 million Gilead collaboration extension payment due in Q4 2026 \u2013 SOUTH SAN FRANCISCO, Calif., Aug. 13, 2026 (GLOBE", "date_published": "2026-08-13T20:00:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "GILD"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "GILD", "name": "Gilead Sciences, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/4671d9b0-cfe6-4289-a9c5-3334d8b946be/"}]}}, {"id": "source:0f4f9816ac288bbbdb5a400fe337aa24cdb4d2657cfc0feb0472fa5db9f39220", "url": "https://finance.yahoo.com/healthcare/articles/gene-therapy-remains-top-mind-185900886.html", "external_url": "https://finance.yahoo.com/healthcare/articles/gene-therapy-remains-top-mind-185900886.html", "title": "Gene Therapy Remains Top-of-Mind in Hemophilia Despite Recent Market Contraction, as Physicians and Patients Raise the Bar for Success", "content_text": "Nearly nine in ten EU4+UK hematologists now require longer-term efficacy data before referring patients with hemophilia A for gene therapy, while Spherix patient research reveals continued interest in the modality. Exton, PA, Aug. 13, 2026 (GLOBE NEWSWIRE) -- The hemophilia gene therapy market is contracting commercially, but physician and patient interest in the modality has not disappeared. Recent commercial developments, including the discontinuation of BEQVEZ\u00ae (Pfizer), withdrawal of ROCTAVIAN\u00ae (BioMarin), and supply challenges for HEMGENIX\u00ae (CSL Behring), have narrowed the available gene ", "date_published": "2026-08-13T18:59:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Macro sensitivity", "PFE"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "PFE", "name": "Pfizer Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/6d38e875-5b6e-4520-a422-46060912e64a/"}]}}, {"id": "source:69a4a7c7fbad651b7d48f5808fc27680e8ea0f4e38147e36a268caab830e0e29", "url": "https://finance.yahoo.com/healthcare/articles/novo-nordisk-stock-slips-pill-183832098.html", "external_url": "https://finance.yahoo.com/healthcare/articles/novo-nordisk-stock-slips-pill-183832098.html", "title": "Novo Nordisk Stock Slips as Pill Strategy Reframes Obesity Race", "content_text": "This article first appeared on GuruFocus. Novo Nordisk (NYSE:NVO), the Danish obesity-drug giant behind Wegovy and Ozempic, slipped approximately 1% Thursday morning as CEO Mike Doustdar tried to reset the market's thinking about the obesity race. His pitch: stop treating Novo versus Eli Lilly (NYSE:LLY) like a winner-takes-all fight. The obesity market could top $100 billion annually by 2030, and different patients will want different drugs, delivery methods and trade-offs. For Novo, that is more than a talking point. It is the heart of the comeback story after Lilly's Zepbound grabbed moment", "date_published": "2026-08-13T18:38:32+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "NNO2", "LLYC"], "_sharemaestro": {"country": "Austria", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "NNO2", "name": "Novo Nordisk A/S", "sentiment_url": "https://sharemaestro.com/sentiment/fcb49788-2486-40a0-adc0-252e820a9044/"}, {"symbol": "LLYC", "name": "Eli Lilly and Company", "sentiment_url": "https://sharemaestro.com/sentiment/445698db-0930-4e3d-97d8-e06e548856f7/"}]}}, {"id": "source:e46340d17e79968c874982ea904781e973354887c194146e1ec14e217f9d295c", "url": "https://finance.yahoo.com/markets/stocks/articles/telstra-stock-slips-1-billion-183752032.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/telstra-stock-slips-1-billion-183752032.html", "title": "Telstra Stock Slips as A$1 Billion Buyback Meets Profit Miss", "content_text": "This article first appeared on GuruFocus. Telstra Group (TLGPY), Australia's largest telecommunications provider, slipped 0.5% in Thursday's early Australian trading. The market's message was pretty clear: another giant buyback was not enough. Telstra unveiled a fresh A$1 billion repurchase program, but annual attributable profit of A$2.24 billion came in below the A$2.30 billion Visible Alpha consensus cited by Reuters. And this is hardly Telstra's first swing at shrinking the share count. The company only finished a separate A$1.25 billion buyback in June. Warning! GuruFocus has detected 4 W", "date_published": "2026-08-13T18:37:52+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Capital return", "NNO2"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "NNO2", "name": "Novo Nordisk A/S", "sentiment_url": "https://sharemaestro.com/sentiment/fcb49788-2486-40a0-adc0-252e820a9044/"}]}}, {"id": "source:d2b8070a7f11de2bcc7d266e2f82a94fb7c534645525c7d5d6d1821803b2ad18", "url": "https://finance.yahoo.com/healthcare/articles/wst-q2-beat-raised-2026-174800503.html", "external_url": "https://finance.yahoo.com/healthcare/articles/wst-q2-beat-raised-2026-174800503.html", "title": "WST Q2 Beat and Raised 2026 Outlook Reinforce the HVP Growth Story", "content_text": "West Pharmaceutical Services, Inc. WST turned a better-than-expected second quarter into a higher 2026 outlook. Organic sales growth accelerated, margins widened and adjusted earnings increased sharply, giving investors a clearer read on how High-Value Product demand is translating into financial performance. The quarter matters because the guidance increase was supported by broad HVP momentum rather than a single product line. Execution risks remain in West Vantage and the SmartDose transition, but the earnings trajectory improved. WST's Q2 Beat Resets 2026 Expectations Adjusted earnings rose", "date_published": "2026-08-13T17:48:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "LLYC", "NNO2"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "LLYC", "name": "Eli Lilly and Company", "sentiment_url": "https://sharemaestro.com/sentiment/445698db-0930-4e3d-97d8-e06e548856f7/"}, {"symbol": "NNO2", "name": "Novo Nordisk A/S", "sentiment_url": "https://sharemaestro.com/sentiment/fcb49788-2486-40a0-adc0-252e820a9044/"}]}}, {"id": "source:a037eecd9aac32645ee2d0d31d4fd7f24611ea1ba15b64b64008f2e6918df676", "url": "https://finance.yahoo.com/markets/stocks/articles/investors-buy-wst-hvp-growth-174800264.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/investors-buy-wst-hvp-growth-174800264.html", "title": "Should Investors Buy WST as HVP Growth Meets a Premium Valuation?", "content_text": "West Pharmaceutical Services, Inc. WST is delivering faster High-Value Product (HVP) growth, wider margins and higher 2026 earnings expectations. Second-quarter organic sales rose 12.7%, while adjusted earnings increased 28.8% to $2.37 per share. The question is whether those gains justify a valuation well above industry levels. WST's growth drivers remain attractive, but the premium multiple leaves less room for operational missteps. WST's HVP Growth Supports the Bull Case HVP Components generated $424.1 million in second-quarter sales, or 49% of total company revenues, and grew 18.4% organic", "date_published": "2026-08-13T17:48:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "LLYC", "NNO2"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "LLYC", "name": "Eli Lilly and Company", "sentiment_url": "https://sharemaestro.com/sentiment/445698db-0930-4e3d-97d8-e06e548856f7/"}, {"symbol": "NNO2", "name": "Novo Nordisk A/S", "sentiment_url": "https://sharemaestro.com/sentiment/fcb49788-2486-40a0-adc0-252e820a9044/"}]}}, {"id": "source:9d26d0c671e6b52bc88015349553cd3b7d1b648cb07b94a61c041492b2d92917", "url": "https://finance.yahoo.com/healthcare/articles/novo-nordisk-escalates-weight-loss-173227558.html", "external_url": "https://finance.yahoo.com/healthcare/articles/novo-nordisk-escalates-weight-loss-173227558.html", "title": "Novo Nordisk Escalates Weight-Loss War With Eli Lilly", "content_text": "This article first appeared on GuruFocus. Novo Nordisk (NYSE:NVO) CEO Mike Doustdar is defending the drugmaker's lawsuit against Eli Lilly (NYSE:LLY), escalating a fight over how the two companies market their blockbuster obesity treatments. The legal battle matters because Lilly has seized the lead in the U.S. obesity-drug market, raising the stakes for Novo as it tries to narrow the efficacy gap consumers may perceive between Wegovy and Zepbound. Is LLY fairly valued? Test your thesis with our free DCF calculator. Novo Nordisk develops treatments for diabetes, obesity and other chronic disea", "date_published": "2026-08-13T17:32:27+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Regulatory and legal", "LLYC", "NNO2"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "LLYC", "name": "Eli Lilly and Company", "sentiment_url": "https://sharemaestro.com/sentiment/445698db-0930-4e3d-97d8-e06e548856f7/"}, {"symbol": "NNO2", "name": "Novo Nordisk A/S", "sentiment_url": "https://sharemaestro.com/sentiment/fcb49788-2486-40a0-adc0-252e820a9044/"}]}}, {"id": "source:b40ec17efd7608a9b538f7a45f663802bba7284e20cc8d0232feee1d3f8ceb2d", "url": "https://finance.yahoo.com/healthcare/articles/novo-nordisks-wegovy-fueled-rebound-172000772.html", "external_url": "https://finance.yahoo.com/healthcare/articles/novo-nordisks-wegovy-fueled-rebound-172000772.html", "title": "Is Novo Nordisk's Wegovy-Fueled Rebound Evaporating?", "content_text": "Novo Nordisk (NYSE: NVO) posted strong first-quarter results and performed fairly well in the month that followed its first-quarter update. However, the company's most recent financial update, for the second quarter, erased much of those gains. In both cases, the market's reaction was largely driven by the performance of the Wegovy pill, the first oral GLP-1 approved for weight loss, which Novo Nordisk launched in the U.S. in January. The Wegovy pill beat expectations in the first quarter but came up short in the second. What does this mean for the company's prospects?Image source: The Motley ", "date_published": "2026-08-13T17:20:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "NNO2", "LLYC"], "_sharemaestro": {"country": "Austria", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "NNO2", "name": "Novo Nordisk A/S", "sentiment_url": "https://sharemaestro.com/sentiment/fcb49788-2486-40a0-adc0-252e820a9044/"}, {"symbol": "LLYC", "name": "Eli Lilly and Company", "sentiment_url": "https://sharemaestro.com/sentiment/445698db-0930-4e3d-97d8-e06e548856f7/"}]}}, {"id": "source:9ffe2c00b2a37cdcea4a80a976a9d7e6f8e3a809762571c555c7e62d96d599f7", "url": "https://finance.yahoo.com/markets/stocks/articles/gilead-gild-stock-still-looks-171104446.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/gilead-gild-stock-still-looks-171104446.html", "title": "Gilead (GILD) Stock Still Looks Cheap On Sales Despite A 127% Run", "content_text": "Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Gilead Sciences stock has delivered a 126.6% total return over the past 5 years, and the current valuation checks still lean on the cheap side rather than pointing to an obvious premium. With that backdrop, investors are weighing whether the recent share price around US$135.87 already reflects the key drivers that have supported the move. A 126.6% return over 5 years suggests Gilead Sciences has rewarded long term holders, so the question is how much of ", "date_published": "2026-08-13T17:11:04+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Balance sheet", "GILD"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "GILD", "name": "Gilead Sciences, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/4671d9b0-cfe6-4289-a9c5-3334d8b946be/"}]}}, {"id": "source:5a0d5b0118aed9417b7f16d5981c04f347cdcc4923eab2e106061425e0ed31a4", "url": "https://finance.yahoo.com/markets/world-indices/articles/european-stocks-close-mixed-thursday-155457527.html", "external_url": "https://finance.yahoo.com/markets/world-indices/articles/european-stocks-close-mixed-thursday-155457527.html", "title": "European Stocks Close Mixed in Thursday Trading; UK GDP Growth Slows in Q2", "content_text": "The European stock markets closed mixed in Thursday trading as The Stoxx Europe edged 0.1% lower, Ge PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in", "date_published": "2026-08-13T15:54:57+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Analyst action", "LLYC", "NNO2"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "LLYC", "name": "Eli Lilly and Company", "sentiment_url": "https://sharemaestro.com/sentiment/445698db-0930-4e3d-97d8-e06e548856f7/"}, {"symbol": "NNO2", "name": "Novo Nordisk A/S", "sentiment_url": "https://sharemaestro.com/sentiment/fcb49788-2486-40a0-adc0-252e820a9044/"}]}}, {"id": "source:099661ecc0bba4c15ccaa35c84a4fa3d5949068502d3e0f1d3319564d315019c", "url": "https://finance.yahoo.com/markets/world-indices/articles/european-equities-traded-us-rise-151440591.html", "external_url": "https://finance.yahoo.com/markets/world-indices/articles/european-equities-traded-us-rise-151440591.html", "title": "European Equities Traded in the US Rise in Thursday Trading", "content_text": "European equities traded in the US as American depositary receipts were higher late Thursday morning, rising 0.45% to 1,969.72 on the S&P Europe Select ADR Index. From continental Europe, the gainers were led by biopharmaceutical company Cellectis (CLLS) and biotech firm Evaxion Silver Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade now", "date_published": "2026-08-13T15:14:40+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Analyst action", "NNO2"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "NNO2", "name": "Novo Nordisk A/S", "sentiment_url": "https://sharemaestro.com/sentiment/fcb49788-2486-40a0-adc0-252e820a9044/"}]}}, {"id": "source:33e32a55454fb0399fcd532ed23175ffd075d37280d0c841a24aff8a18065e15", "url": "https://finance.yahoo.com/healthcare/articles/pfizer-higher-2026-guidance-litfulo-151241315.html", "external_url": "https://finance.yahoo.com/healthcare/articles/pfizer-higher-2026-guidance-litfulo-151241315.html", "title": "How Pfizer\u2019s Higher 2026 Guidance And LITFULO Trial Results At Pfizer (PFE) Have Changed Its Investment Story", "content_text": "In early August 2026, Pfizer Inc. reported second-quarter results showing revenue of US$15,034 million and a net loss of US$248 million, alongside US$4.30 billion in non-cash intangible asset impairments and a modest increase in full-year 2026 revenue guidance to US$60.50\u2013US$62.50 billion. A key offsetting highlight was the positive Phase 3 data for Pfizer's autoimmune drug LITFULO in nonsegmental vitiligo, underlining the growing importance of its non-COVID portfolio and broader immunology and dermatology pipeline. We'll now explore how Pfizer's higher 2026 revenue guidance, backed by non-COV", "date_published": "2026-08-13T15:12:41+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "PFE"], "_sharemaestro": {"country": "Austria", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "PFE", "name": "Pfizer Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/6d38e875-5b6e-4520-a422-46060912e64a/"}]}}, {"id": "source:ec826990d2c6b2707cb2345a499149ef75cc010896670e707947cc069f7f222f", "url": "https://finance.yahoo.com/healthcare/articles/novo-nordisk-cpse-novo-b-151234003.html", "external_url": "https://finance.yahoo.com/healthcare/articles/novo-nordisk-cpse-novo-b-151234003.html", "title": "Novo Nordisk (CPSE:NOVO B) Sees New Pressure In Weight Loss Drugs", "content_text": "Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Novo Nordisk (CPSE:NOVO B) faces fresh competition as the UK's MHRA approves Eli Lilly's oral weight loss therapy Foundayo for use in the country. The approval adds a non injectable option alongside Novo Nordisk's GLP 1 based obesity drugs and could affect demand patterns if Foundayo is adopted in public healthcare settings. In the US, Amazon Pharmacy launches a new Medicare weight loss drug program priced at $50 per month that will include Novo Nordisk an", "date_published": "2026-08-13T15:12:34+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "LLYC", "NNO2"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "LLYC", "name": "Eli Lilly and Company", "sentiment_url": "https://sharemaestro.com/sentiment/445698db-0930-4e3d-97d8-e06e548856f7/"}, {"symbol": "NNO2", "name": "Novo Nordisk A/S", "sentiment_url": "https://sharemaestro.com/sentiment/fcb49788-2486-40a0-adc0-252e820a9044/"}]}}, {"id": "source:21cdd6efb4f006a77a1ccec8b3e58b1a3934172bb51c9e54a5a601ca9f190457", "url": "https://finance.yahoo.com/media-advertising/articles/advertising-research-foundation-announces-2026-150200996.html", "external_url": "https://finance.yahoo.com/media-advertising/articles/advertising-research-foundation-announces-2026-150200996.html", "title": "The Advertising Research Foundation Announces 2026 ARF David Ogilvy Awards Finalists", "content_text": "NEW YORK, Aug. 13, 2026 /PRNewswire/ -- The Advertising Research Foundation (ARF) today announced the finalists for the 2026 ARF David Ogilvy Awards, honoring excellence in research-driven advertising and marketing. For more than 30 years, the ARF David Ogilvy Awards have recognized campaigns that demonstrate how consumer insights and research can inspire creative work that delivers measurable business results. This year's finalists represent leading brands across categories including Automotive, B2B, Cultural Fluency, Financial Services & Insurance, Food & Beverage, Health & Personal Care, Be", "date_published": "2026-08-13T15:02:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "PFE"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "PFE", "name": "Pfizer Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/6d38e875-5b6e-4520-a422-46060912e64a/"}]}}, {"id": "source:1bf83bc90c892913c96d9159dc11f2436f52e3155ab02f2e8fc6269a170353e1", "url": "https://www.nasdaq.com/articles/noteworthy-etf-outflows-tqqq-adi-mrvl-gild", "external_url": "https://www.nasdaq.com/articles/noteworthy-etf-outflows-tqqq-adi-mrvl-gild", "title": "Noteworthy ETF Outflows: TQQQ, ADI, MRVL, GILD", "content_text": "Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the ProShares UltraPro QQQ (Symbol: TQQQ) where we have detected an approximate $156.7 million dollar outflow -- that's a 0.4% decrease week over week (from 506,050,000 to 503,950,000). Among the largest underlying components of TQQQ, in trading today Analog Devices Inc (Symbol: ADI) is up about 0.8%, Marvell Technology Inc (Symbol: MRVL) is up about 4.9%, and Gilead Sciences Inc (Symbol: GILD) is up by about 1%. For a complete list of holdings, visit the TQQQ Holdings ", "date_published": "2026-08-13T14:49:26+00:00", "authors": [{"name": "nasdaq.com"}], "tags": ["Market update", "GILD"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "GILD", "name": "Gilead Sciences, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/4671d9b0-cfe6-4289-a9c5-3334d8b946be/"}]}}, {"id": "source:db71b0b296aedbce1995a29b5568dcd4026f0c736ce1e90097a67b9907424050", "url": "https://finance.yahoo.com/healthcare/articles/cvs-health-enhances-direct-consumer-143000440.html", "external_url": "https://finance.yahoo.com/healthcare/articles/cvs-health-enhances-direct-consumer-143000440.html", "title": "CVS Health Enhances Its Direct-to-Consumer Weight Management Offerings To Improve Access, Affordability, Care and Support for GLP-1 Medications", "content_text": "WOONSOCKET, RI / ACCESS Newswire / August 13, 2026 / Originally published on CVS Health Company Newsroom CVS Pharmacy offers all FDA approved GLP-1s, whether through insurance or cash-pay options. New collaboration with Eli Lilly and Company will provide eligible Zepbound and Foundayo patients an additional access point at CVS Pharmacy through the CVS Health app MinuteClinic digital weight loss visits lowered to $29, the most affordable option in the market, available 24/7 Combines an online visit with a licensed clinician, same-day medication pickup at 9,000 local CVS Pharmacy locations, and ", "date_published": "2026-08-13T14:30:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "LLYC"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "LLYC", "name": "Eli Lilly and Company", "sentiment_url": "https://sharemaestro.com/sentiment/445698db-0930-4e3d-97d8-e06e548856f7/"}]}}, {"id": "source:285cd116450d19c84ebc238b53aebf9d2f68170dd87757a5fed39d74f6c4c85b", "url": "https://finance.yahoo.com/healthcare/articles/novo-nordisks-glp-1-pill-142600733.html", "external_url": "https://finance.yahoo.com/healthcare/articles/novo-nordisks-glp-1-pill-142600733.html", "title": "Can Novo Nordisk's GLP-1 Pill Momentum Offset LLY's Growing Edge?", "content_text": "Novo Nordisk NVO remains a dominant player in the GLP-1 market, marketing its semaglutide drugs Ozempic and Rybelsus for type II diabetes (T2D) and Wegovy for chronic weight management. However, the company's core franchise is facing mounting competitive pressure from Eli Lilly LLY, despite NVO delivering a better-than-expected second-quarter 2026 performance. NVO's reported second-quarter sales rose 3% to $12.21 billion (DKK 78.5 billion) at constant exchange rates (CER). More importantly, its key GLP-1 brands showed signs of slowing. Ozempic generated $4.88 billion (DKK 31.4 billion) in repo", "date_published": "2026-08-13T14:26:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "LLYC", "NNO2"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "LLYC", "name": "Eli Lilly and Company", "sentiment_url": "https://sharemaestro.com/sentiment/445698db-0930-4e3d-97d8-e06e548856f7/"}, {"symbol": "NNO2", "name": "Novo Nordisk A/S", "sentiment_url": "https://sharemaestro.com/sentiment/fcb49788-2486-40a0-adc0-252e820a9044/"}]}}, {"id": "source:da0297559d651677418fbbf2281dc586889c01c0c9a0ba40b54c6abb3d366400", "url": "https://finance.yahoo.com/markets/stocks/articles/2-p-500-stocks-exciting-140500822.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/2-p-500-stocks-exciting-140500822.html", "title": "2 S&P 500 Stocks with Exciting Potential and 1 We Ignore", "content_text": "2 S&P 500 Stocks with Exciting Potential and 1 We Ignore The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition. Picking the right S&P 500 stocks requires more than just buying big names, and that's where StockStory comes in. That said, here are two S&P 500 stocks that could deliver good returns and one that may struggle. One Stock to Sell: Hartford (HIG) Market Cap: $38.23", "date_published": "2026-08-13T14:05:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "LLYC"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "LLYC", "name": "Eli Lilly and Company", "sentiment_url": "https://sharemaestro.com/sentiment/445698db-0930-4e3d-97d8-e06e548856f7/"}]}}, {"id": "source:101ca26192ab6e98d81cd342a73465bb4ea3b94c3cf4262e0826f541a1f35522", "url": "https://finance.yahoo.com/healthcare/articles/keytruda-sustain-mercks-growth-second-140000696.html", "external_url": "https://finance.yahoo.com/healthcare/articles/keytruda-sustain-mercks-growth-second-140000696.html", "title": "Can Keytruda Sustain Merck's Growth in the Second Half of 2026?", "content_text": "Merck's MRK strong foothold in the oncology space is backed by its biggest revenue driver, Keytruda. The blockbuster PD-L1 inhibitor alone accounts for more than 55% of the company's total pharmaceutical sales. In the United States, Keytruda is approved for 44 indications spanning 19 tumor types, along with two tumor-agnostic approvals as well as for many of these indications worldwide. Notably, more than 2,800 clinical studies are currently evaluating Keytruda across multiple cancer types and treatment settings. Keytruda, approved for several types of cancers, has played an instrumental role ", "date_published": "2026-08-13T14:00:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "ROGH"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "ROGH", "name": "Roche Holding AG", "sentiment_url": "https://sharemaestro.com/sentiment/dcb04c87-d9c1-4862-a5fb-05554dd11be7/"}]}}, {"id": "source:f3fab633d584d08932a2870ce562c4f22cbee989985bd7c4a16774be1769ba11", "url": "https://finance.yahoo.com/healthcare/articles/wolfe-research-upgrades-biogen-abbvie-135201210.html", "external_url": "https://finance.yahoo.com/healthcare/articles/wolfe-research-upgrades-biogen-abbvie-135201210.html", "title": "Wolfe Research upgrades Biogen, AbbVie on pipeline strength and valuation", "content_text": "Investing.com -- Wolfe Research upgraded two major pharmaceutical companies to Outperform on Thursday, citing stronger growth prospects, attractive valuations and a series of upcoming clinical catalysts. For Biogen, Wolfe raised its rating from Peer Perform and set a $300 price target, arguing that the company's late-stage pipeline offers significant upside that is not fully reflected in current valuations. The firm highlighted litifilimab and felzartamab as key assets, with clinical readouts expected over the coming year. Wolfe said litifilimab could become the first biologic approved for cut", "date_published": "2026-08-13T13:52:01+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Analyst action", "BIIB"], "_sharemaestro": {"country": "Austria", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "BIIB", "name": "Biogen Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/d8a518cd-faae-411d-9e51-ae691d378355/"}]}}, {"id": "source:680781d62dcbd5eeeeb19a08182cf19c2622f9db2db673e90b75e3356e08f20a", "url": "https://finance.yahoo.com/healthcare/articles/llys-foundayo-posts-98m-q2-134200240.html", "external_url": "https://finance.yahoo.com/healthcare/articles/llys-foundayo-posts-98m-q2-134200240.html", "title": "LLY's Foundayo Posts $98M in Q2 Sales: What's Next for the Oral GLP-1?", "content_text": "Eli Lilly and Company LLY announced second-quarter results on Aug. 5. Investors were keen to know the first sales numbers and initial launch uptake of Lilly's new once-daily oral GLP-1 pill, Foundayo (orforglipron) for treating obesity, which was launched in April. Foundayo (orforglipron) generated $98 million in sales in the second quarter, its first full quarter on the market. Lilly expects Foundayo to be a commercial game-changer for the company as oral pills are expected to be a more convenient alternative to the currently available once-weekly injectable obesity treatments like Lilly's Ze", "date_published": "2026-08-13T13:42:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "LLYC", "NNO2"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "LLYC", "name": "Eli Lilly and Company", "sentiment_url": "https://sharemaestro.com/sentiment/445698db-0930-4e3d-97d8-e06e548856f7/"}, {"symbol": "NNO2", "name": "Novo Nordisk A/S", "sentiment_url": "https://sharemaestro.com/sentiment/fcb49788-2486-40a0-adc0-252e820a9044/"}]}}, {"id": "source:cb06f6881a4ca0938732efe5068ee1c6a1d658b8fcc1c0e0dcadc224181ff274", "url": "https://finance.yahoo.com/healthcare/articles/opko-health-expands-strategic-relationship-131500140.html", "external_url": "https://finance.yahoo.com/healthcare/articles/opko-health-expands-strategic-relationship-131500140.html", "title": "OPKO Health Expands Strategic Relationship with HealthCare Royalty Through $125 Million Notes Issuance Secured by Mazdutide Royalty Interests", "content_text": "OPKO Health, Inc. Transaction provides additional non-dilutive capital and enhanced financial flexibility while preserving meaningful long-term royalty upside MIAMI, Fla., Aug. 13, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced the expansion of its financing relationship with HealthCare Royalty, a business of KKR (HCRx), through the issuance of an additional $125 million aggregate principal amount of senior secured notes. The newly issued notes are secured by OPKO's royalty interests arising under its mazdutide license agreement with Eli Lilly and Company and mature i", "date_published": "2026-08-13T13:15:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "LLYC"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "LLYC", "name": "Eli Lilly and Company", "sentiment_url": "https://sharemaestro.com/sentiment/445698db-0930-4e3d-97d8-e06e548856f7/"}]}}, {"id": "source:abc8622d32621fa12aa741e3e18cc688963e7c916e85cf11b5df370c94aebe19", "url": "https://finance.yahoo.com/markets/stocks/articles/pfizer-ceo-buys-1-million-122046176.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/pfizer-ceo-buys-1-million-122046176.html", "title": "Pfizer CEO Buys $1 Million of Stock", "content_text": "This article first appeared on GuruFocus. Pfizer Inc. (PFE, Financials) The pharmaceutical giant earned a new vote of confidence from its top executive. Albert Bourla bought about $1 million worth of company stock. Bourla purchased 38,000 shares at $26.34 apiece, which increased his ownership interest to 429,172 shares.The reason people watch insider buying is that CEOs are already compensated very well based on how well the firm does, so buying shares on the open market is more interesting than receiving stock as part of a regular pay package.The decision comes as Pfizer also seeks to persuad", "date_published": "2026-08-13T12:20:46+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "PFE"], "_sharemaestro": {"country": "Austria", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "PFE", "name": "Pfizer Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/6d38e875-5b6e-4520-a422-46060912e64a/"}]}}, {"id": "source:6a718becf991eeeaf34cd79c446bedd27ee9e3434e04d0e0d2465e2556e48a95", "url": "https://finance.yahoo.com/m/5ca00ec7-60e3-37e1-afbf-424b9fe2957d/this-healthcare-services.html", "external_url": "https://finance.yahoo.com/m/5ca00ec7-60e3-37e1-afbf-424b9fe2957d/this-healthcare-services.html", "title": "This Healthcare Services Stock Has 37% Upside", "content_text": "Well-known pharmaceutical companies such as Merck and Pfizer typically manage this complex process in house. Medpace Holdings which targets oncology, metabolic, cardiology, central nervous system, and anti-infective therapies, raised its 2026 revenue guidance on July\u2019s second-quarter conference call to a midpoint of $2.85 billion, corresponding to a year-over-year increase of 13%. Three months later, Medpace is in the pink: On the heels of second-quarter earnings, the stock is up 14%. Continue Reading", "date_published": "2026-08-13T12:01:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "MRK", "PFE"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "MRK", "name": "Merck & Co., Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/0211e6e8-c5d1-4887-83fc-5f88917de5ec/"}, {"symbol": "PFE", "name": "Pfizer Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/6d38e875-5b6e-4520-a422-46060912e64a/"}]}}, {"id": "source:1fb430f4d1b71b75f67c6b22999fe9bcfcc63d54812fb79c7524b788dcf10acc", "url": "https://finance.yahoo.com/markets/stocks/articles/invesco-dividend-achievers-etf-pfm-102001482.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/invesco-dividend-achievers-etf-pfm-102001482.html", "title": "Should Invesco Dividend Achievers ETF (PFM) Be on Your Investing Radar?", "content_text": "Designed to provide broad exposure to the Large Cap Value segment of the US equity market, the Invesco Dividend Achievers ETF (PFM) is a passively managed exchange traded fund launched on September 15, 2005. The fund is sponsored by Invesco. It has amassed assets over $812.25 million, making it one of the average sized ETFs attempting to match the Large Cap Value segment of the US equity market. Why Large Cap Value Large cap companies usually have a market capitalization above $10 billion. Considered a more stable option, large cap companies boast more predictable cash flows and are less volat", "date_published": "2026-08-13T10:20:01+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "LLYC"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "LLYC", "name": "Eli Lilly and Company", "sentiment_url": "https://sharemaestro.com/sentiment/445698db-0930-4e3d-97d8-e06e548856f7/"}]}}, {"id": "source:79ac6a4212879c1730f4d9d7d98c7f0bb6fab689172f414cdbb637101d7d0624", "url": "https://finance.yahoo.com/healthcare/articles/why-gilead-sciences-gild-back-091117191.html", "external_url": "https://finance.yahoo.com/healthcare/articles/why-gilead-sciences-gild-back-091117191.html", "title": "Why Gilead Sciences (GILD) Is Back In The Spotlight", "content_text": "Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Gilead Sciences (GILD) is back in focus after announcing a collaboration with Nucleai that applies AI powered tissue analytics to its antibody drug conjugate programs, with the goal of speeding biomarker discovery across its oncology pipeline. See our latest analysis for Gilead Sciences. At a share price of $135.87, Gilead Sciences has posted an 11.74% year to date share price return and a 16.04% total shareholder return over the past year. Longer term total shareholder retur", "date_published": "2026-08-13T09:11:17+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Capital return", "GILD"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "GILD", "name": "Gilead Sciences, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/4671d9b0-cfe6-4289-a9c5-3334d8b946be/"}]}}, {"id": "source:5c3175630e88f5bc7762b7912b48c5c2bb9979bfb25b28db4bab7aa1d85378b1", "url": "https://finance.yahoo.com/healthcare/articles/spero-therapeutics-inc-spro-q2-050124333.html", "external_url": "https://finance.yahoo.com/healthcare/articles/spero-therapeutics-inc-spro-q2-050124333.html", "title": "Spero Therapeutics Inc (SPRO) (Q2 2026) Earnings Call Highlights: FDA Approval of Utebzi and ...", "content_text": "This article first appeared on GuruFocus. Cash and Cash Equivalents: $50.8 million as of June 30, 2026, excluding net proceeds from the July 2026 royalty financing. Revenue: No revenue for Q2 2026, compared to $14.2 million in Q2 2025, primarily due to prior collaboration revenue from Pfizer and GSK being fully realized. R&D Expenses: $3.4 million in Q2 2026, down from $10.7 million in Q2 2025, due to reduced clinical activity following the early completion of the Utebzi Phase 3 trial. G&A Expenses: $6.5 million in Q2 2026, up from $5.9 million in Q2 2025, driven by higher business development", "date_published": "2026-08-13T05:01:24+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "PFE"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "PFE", "name": "Pfizer Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/6d38e875-5b6e-4520-a422-46060912e64a/"}]}}, {"id": "source:cd43458cb731296f7072733bebb601944bde7b3165366430c94af54a3ae6c0ff", "url": "https://finance.yahoo.com/healthcare/articles/valneva-reports-half-2026-financial-050000261.html", "external_url": "https://finance.yahoo.com/healthcare/articles/valneva-reports-half-2026-financial-050000261.html", "title": "Valneva Reports Half Year 2026 Financial Results and Provides Corporate Updates", "content_text": "VALNEVA SE Total product sales of \u20ac64.0 million In-line with expectations; full-year guidance of \u20ac135 -150 million reaffirmed Solid cash position of \u20ac121.5 million as of end June 2026 Reflects disciplined cash management and proceeds from the recent reserved offering1 Restructuring program implemented with positive P&L and cash flow impacts expected in the second half of the year and beyond Regulatory decisions for Lyme disease vaccine candidate expected in the next twelve months2 Pfizer remains optimistic about obtaining registration for the vaccine candidate3 Lyon (France), August 13, 2026 \u2013", "date_published": "2026-08-13T05:00:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "PFE"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "PFE", "name": "Pfizer Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/6d38e875-5b6e-4520-a422-46060912e64a/"}]}}, {"id": "source:c9105537991a2410bc7664b3b56579e151726bb5f2cfc3df9682a814d45fcc98", "url": "https://finance.yahoo.com/healthcare/articles/5-must-read-analyst-questions-042100262.html", "external_url": "https://finance.yahoo.com/healthcare/articles/5-must-read-analyst-questions-042100262.html", "title": "5 Must-Read Analyst Questions From Gilead Sciences\u2019s Q2 Earnings Call", "content_text": "5 Must-Read Analyst Questions From Gilead Sciences's Q2 Earnings Call Gilead Sciences delivered a solid Q2, with year-over-year sales growth led by strong demand in its HIV franchise, particularly Biktarvy and the PrEP segment, as well as advances in oncology and liver disease. Management credited commercial execution and new product launches\u2014including Trodelvy in breast cancer and Livdelzi in liver disease\u2014for boosting results. CEO Daniel O'Day highlighted, \"Quarterly PrEP sales doubled year-over-year, exceeding $1 billion for the first time,\" underscoring the impact of portfolio expansion. T", "date_published": "2026-08-13T04:21:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "GILD"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "GILD", "name": "Gilead Sciences, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/4671d9b0-cfe6-4289-a9c5-3334d8b946be/"}]}}, {"id": "source:ca7bd9b0749ebb6a787227418d9a91b874566d623be8c3cd9e785328575d4a6f", "url": "https://finance.yahoo.com/healthcare/articles/5-insightful-analyst-questions-pfizer-022900266.html", "external_url": "https://finance.yahoo.com/healthcare/articles/5-insightful-analyst-questions-pfizer-022900266.html", "title": "5 Insightful Analyst Questions From Pfizer\u2019s Q2 Earnings Call", "content_text": "5 Insightful Analyst Questions From Pfizer's Q2 Earnings Call Pfizer's second quarter results reflected stability in its core business despite ongoing challenges in COVID-related product demand. The company's performance was shaped by strong execution in its non-COVID portfolio, with management highlighting robust revenue contributions from acquired brands and recent launches. CEO Albert Bourla attributed operational progress to \"continued strategic progress\" and emphasized the value generated by recent acquisitions such as Seagen and Biohaven. Management also pointed to the success of brands ", "date_published": "2026-08-13T02:29:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "PFE"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "PFE", "name": "Pfizer Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/6d38e875-5b6e-4520-a422-46060912e64a/"}]}}, {"id": "source:f594c50a2829c0bc45dda3d205dd186eb2ff4b9d76ef9412fb23e929f303f7e5", "url": "https://finance.yahoo.com/healthcare/articles/5-insightful-analyst-questions-merck-234100386.html", "external_url": "https://finance.yahoo.com/healthcare/articles/5-insightful-analyst-questions-merck-234100386.html", "title": "5 Insightful Analyst Questions From Merck\u2019s Q2 Earnings Call", "content_text": "5 Insightful Analyst Questions From Merck's Q2 Earnings Call Merck's second quarter was marked by continued sales growth, primarily driven by the strength of its oncology portfolio and contributions from new product launches. Management credited higher demand for KEYTRUDA in both early-stage and metastatic cancers and robust performance in Animal Health as core drivers. CFO Caroline Litchfield highlighted, \"Our strong commercial and operational execution continues to drive near-term performance while we invest in our outstanding pipeline.\" While market reaction was muted, management acknowledg", "date_published": "2026-08-12T23:41:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "MRK"], "_sharemaestro": {"country": "Austria", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "MRK", "name": "Merck & Co., Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/0211e6e8-c5d1-4887-83fc-5f88917de5ec/"}]}}, {"id": "source:5fcdf767edc608cff7fa5cd79c787c8ad280036dafb0cd1562c8c5a696de8af4", "url": "https://finance.yahoo.com/healthcare/articles/sector-healthcare-stocks-advance-afternoon-195841095.html", "external_url": "https://finance.yahoo.com/healthcare/articles/sector-healthcare-stocks-advance-afternoon-195841095.html", "title": "Sector Update: Healthcare Stocks Advance Late Afternoon", "content_text": "Healthcare stocks were higher late Wednesday afternoon, with the NYSE Healthcare Index up 0.2% and t PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in", "date_published": "2026-08-12T19:58:41+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Analyst action", "MRK"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "MRK", "name": "Merck & Co., Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/0211e6e8-c5d1-4887-83fc-5f88917de5ec/"}]}}, {"id": "source:c8bfa06c7b9fbc27fe482807c5f11f2a9d5007b55d87a343f2383b67a9ff8c80", "url": "https://finance.yahoo.com/healthcare/articles/bmys-growth-portfolio-strong-enough-183600346.html", "external_url": "https://finance.yahoo.com/healthcare/articles/bmys-growth-portfolio-strong-enough-183600346.html", "title": "Is BMY's Growth Portfolio Strong Enough to Offset Legacy Drug Declines?", "content_text": "Bristol Myers Squibb BMY is navigating a revenue mix shift as growth products portfolio now assumes a larger role in the business, helping mitigate the impact of declining sales from mature products facing generics. The growth portfolio \u2014 including Opdivo, Opdivo Qvantig, Orencia, Yervoy, Reblozyl, Camzyos, Breyanzi, Opdualag, Zeposia, Sotyku, Krazati and Cobenfy \u2014 is becoming central to top-line resilience. Sales from this segment rose 13% in the first half of 2026, lifting its contribution to 56% of total revenues from 51.8% in the first half of 2025. The stronger mix underscores improving r", "date_published": "2026-08-12T18:36:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "MRK", "PFE"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "MRK", "name": "Merck & Co., Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/0211e6e8-c5d1-4887-83fc-5f88917de5ec/"}, {"symbol": "PFE", "name": "Pfizer Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/6d38e875-5b6e-4520-a422-46060912e64a/"}]}}, {"id": "source:91fbd6c7e56500b236257767bf61f9a38e6f84db47b9c0d6b62395e27b1fa08e", "url": "https://seekingalpha.com/news/4631770-tigo-energy-downgraded-at-roth-after-weak-revenue-guidance?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "external_url": "https://seekingalpha.com/news/4631770-tigo-energy-downgraded-at-roth-after-weak-revenue-guidance?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "title": "Tigo Energy downgraded at Roth after weak revenue guidance", "content_text": "[Aerial view of large electrical power plant with many rows of solar photovoltaic panels for producing clean ecological electric energy in morning. Renewable electricity with zero emission concept.] Bilanol/iStock via Getty Images Tigo Energy (TYGO [https://seekingalpha.com/symbol/TYGO]) down 5.2% in Wednesday's trading as Roth Capital downgraded shares of the solar and energy storage firm to Neutral from Buy with a $1.30 price target, slashed from $7 previously, reflecting \"materially weaker growth visibility\" following its Q2 results. Tigo Energy (TYGO [https://seekingalpha.com/symbol/TYGO])", "date_published": "2026-08-12T18:21:16+00:00", "authors": [{"name": "seekingalpha.com"}], "tags": ["Earnings", "PFE"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "PFE", "name": "Pfizer Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/6d38e875-5b6e-4520-a422-46060912e64a/"}]}}, {"id": "source:d9683bb69f74210c4baa0a6b901098dea0f33f985349c2426ac47e1792858586", "url": "https://finance.yahoo.com/healthcare/articles/gilead-sciences-gild-expands-adc-181350587.html", "external_url": "https://finance.yahoo.com/healthcare/articles/gilead-sciences-gild-expands-adc-181350587.html", "title": "Gilead Sciences (GILD) Expands ADC Research With AI Tissue Analytics", "content_text": "Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Gilead Sciences (NasdaqGS:GILD) announced a partnership with Nucleai to use AI-powered tissue analytics in its global antibody drug conjugate programs. The collaboration focuses on translational research to speed up biomarker discovery and support precision oncology development. The AI tools are intended to help standardize and accelerate analysis of tumor samples across Gilead's oncology pipeline. Gilead is not the only company leaning into AI to reshap", "date_published": "2026-08-12T18:13:50+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Deals and strategy", "GILD"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "GILD", "name": "Gilead Sciences, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/4671d9b0-cfe6-4289-a9c5-3334d8b946be/"}]}}, {"id": "source:fef18f4e280685de7dbc6c50d1d93df3658df1ac06d7c1efcd63083fe71bf0e5", "url": "https://finance.yahoo.com/healthcare/articles/berenberg-cuts-novo-nordisk-lilly-172911933.html", "external_url": "https://finance.yahoo.com/healthcare/articles/berenberg-cuts-novo-nordisk-lilly-172911933.html", "title": "Berenberg Cuts Novo Nordisk as Lilly Takes the Oral Market", "content_text": "This article first appeared on GuruFocus. Novo Nordisk (NYSE:NVO), the Danish drugmaker behind Wegovy and Ozempic, fell 2.23% intraday after Berenberg downgraded the stock to Hold from Buy, cutting its Copenhagen target to DKK 305 from DKK 325 and its ADR target to $47 from $50. Analyst Kerry Holford argues that the Wegovy pill upside her Buy rating was built on has already played out. Warning! GuruFocus has detected 3 Warning Sign with NVO. Is NVO fairly valued? Test your thesis with our free DCF calculator. Berenberg and broader consensus now model around DKK 15 billion of Wegovy pill sales ", "date_published": "2026-08-12T17:29:11+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Analyst action", "LLYC", "NNO2"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "LLYC", "name": "Eli Lilly and Company", "sentiment_url": "https://sharemaestro.com/sentiment/445698db-0930-4e3d-97d8-e06e548856f7/"}, {"symbol": "NNO2", "name": "Novo Nordisk A/S", "sentiment_url": "https://sharemaestro.com/sentiment/fcb49788-2486-40a0-adc0-252e820a9044/"}]}}, {"id": "source:9ea2ad3466fa89ef19f9ade7b95f627db7c366dc80cbdf58a5e5a3b73c6f014e", "url": "https://finance.yahoo.com/healthcare/articles/eli-lilly-stock-falls-while-172418737.html", "external_url": "https://finance.yahoo.com/healthcare/articles/eli-lilly-stock-falls-while-172418737.html", "title": "Eli Lilly Stock Falls While Retatrutide Lawsuits Expand", "content_text": "This article first appeared on GuruFocus. Eli Lilly (NYSE:LLY), the drug giant sitting at the center of the obesity boom, filed six lawsuits against businesses it says are illegally selling retatrutide. The timing is striking. Retatrutide is not approved. It is still in Phase 3 trials. Yet Lilly says compounding pharmacies, medical spas and online vendors are already pushing unauthorized versions for human use, sometimes hiding behind research use only labels. Lilly shares slipped roughly 0.8% Wednesday morning, but this fight is much bigger than one day's stock move. Lilly is defending a drug", "date_published": "2026-08-12T17:24:18+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Regulatory and legal", "LLYC"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "LLYC", "name": "Eli Lilly and Company", "sentiment_url": "https://sharemaestro.com/sentiment/445698db-0930-4e3d-97d8-e06e548856f7/"}]}}]}